p16阳性与阴性头颈部鳞状细胞癌原发放疗后高剂量局部区域失败模式——DAHANCA 19研究
该研究分析DAHANCA 19随机试验中608例接受根治性IMRT(±顺铂)联合尼莫拉唑的头颈部鳞状细胞癌患者,151例五年内出现局部区域失败,收集130对计划CT与诊断扫描进行形变配准。80%患者至少一个失败点位于95%处方剂量覆盖区内,67%失败点位于高剂量CTV1内,p16阳性口咽癌黏膜和淋巴结失败多数被根治剂量覆盖,p16阴性肿瘤分别为75%和66%,结论为放射抵抗是无论HPV/p16状态的原发放疗失败主要原因。
要点
- 130例局部区域失败患者中104例(80%)至少一个失败点被95%处方剂量覆盖。
- 87例(67%)失败点起源位于高剂量CTV1内。
- p16阳性口咽癌黏膜失败84%、淋巴结失败61%被根治剂量覆盖;p16阴性肿瘤分别为75%和66%。
核心结论
- 放射抵抗是头颈部鳞状细胞癌原发放疗失败的主要原因,与HPV/p16状态无关。
- 作者认为需要关注放疗反应的预测因素,以识别高剂量失败风险较高的患者,这些患者可能从强化治疗方案中获益。
研究设计与样本
- DAHANCA 19随机对照试验中2007年至12月纳入的608例口腔、口咽、下咽或喉部头颈部鳞状细胞癌患者,接受根治性IMRT(±顺铂)联合尼莫拉唑治疗。
- 151例患者五年内出现局部区域失败,收集其中130对计划CT与诊断失败扫描进行形变配准。
- 采用基于起源点的失败模式分析,包括与CTV1和GTV的距离以及起源点的估计剂量覆盖。
主要发现
- 130例配对扫描患者中,104例(80%)至少一个局部或区域失败点被95%处方剂量覆盖。
- 87例(67%)失败点的起源位于高剂量CTV1内。
- p16阳性口咽癌失败中,黏膜失败84%和淋巴结失败61%被根治剂量覆盖。
- p16阴性肿瘤(口腔、p16阴性口咽、下咽和喉)中,75%黏膜失败和66%淋巴结失败为高剂量失败。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Patients with failure after primary radiotherapy (RT) for head and neck squamous cell carcinoma (HNSCC) have a poor prognosis. This study investigates pattern of failure after primary curatively intended IMRT in a randomized controlled trial in relation to HPV/p16 status. MATERIAL AND METHODS: Patients with HNSCC of the oral cavity, oropharynx (OPSCC), hypopharynx or larynx were treated with primary curative IMRT (+/-cisplatin) and concomitant nimorazole between 2007 and 12. Of 608 patients, 151 had loco-regional failure within five years, from whom 130 pairs of scans (planning-CT and diagnostic failure scan) were collected and deformably co-registered. Point of origin-based pattern of failure analysis was conducted, including distance to CTV1 and GTV, and estimated dose coverage of the point of origin. RESULTS: Of 130 patients with pairs of scans, 104 (80 %) had at least one local or regional failure site covered by 95 % of prescribed dose and 87 (67 %) of the failures had point of origin within the high-dose CTV (CTV1). Of failures from primary p16 + OPSCC, the majority of both mucosal (84 %) and nodal (61 %) failures were covered by curative doses. For p16- tumors (oral cavity, OPSCC p16neg, hypopharynx and larynx), 75 % of mucosal and 66 % of nodal failures were high-dose failures. CONCLUSION: Radioresistance is the primary cause of failure after RT for HNSCC irrespective of HPV/p16 status. Thus, focus on predictors for the response to RT is warranted to identify patients with higher risk of high-dose failure that might benefit from intensified treatment regimens.
引用
- Kristensen MH, Holm AIS, Hansen CR, et al. High-dose loco-regional pattern of failure after primary radiotherapy in p16 positive and negative head and neck squamous cell carcinoma - A DAHANCA 19 study. Clin Transl Radiat Oncol. 2024. PMID: 38596816. doi:10.1016/j.ctro.2024.100772
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。